The CLS team at the AUA2023. Right to Left: Lotta Nilsson,VP Marketing, CLS AB; Rick Wilderotter, Director, Business Development, CLS America’s Inc.; Michael Magnani, President, CLS America’s Inc., and Amani Abou-Zamzam MBA, Urology Strategy Consultant. Joel Hix, Director, Clinical Operations, CLS America’s Inc. (not pictured).
CLS also hosted a private KOL dinner reception where Dr. Fernando Bianco was able to share some early results from our first office-based focal laser ablation cases in America. The first twenty patients have been safely treated and follow up is now ongoing.
Read more about the study here.
Want to learn more about our 510(k) cleared TRANBERG™ products and latest news?
Fill out the form below and we´ll contact you.
Phone:+1 (949) 504-5440
Phone: +1 (480)363-8774
Our latest news are displayed below (links to CLS America webpage).
We are happy to share that CLS Americas has entered into an agreement with Genesis Research, LLC, an affiliate of Unio Health Partners, to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”
Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.
We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region